Skip to content
Pacritinib
Vonjo (pacritinib) is a small molecule pharmaceutical. Pacritinib was first approved as Vonjo on 2022-02-28. It is used to treat primary myelofibrosis in the USA. The pharmaceutical is active against tyrosine-protein kinase JAK2. In addition, it is known to target tyrosine-protein kinase JAK1, receptor-type tyrosine-protein kinase FLT3, tyrosine-protein kinase JAK3, and ribosyldihydronicotinamide dehydrogenase [quinone].
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
Trade Name
FDA
EMA
Vonjo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pacritinib citrate
Tradename
Company
Number
Date
Products
VONJOCTI BiopharmaN-208712 RX2022-02-28
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
vonjoNew Drug Application2022-03-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
primary myelofibrosis—D055728D47.4
Agency Specific
FDA
EMA
Expiration
Code
PACRITINIB CITRATE, VONJO, CTI BIOPHARMA CORP
2029-02-28ODE-397
2027-02-28NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Pacritinib Citrate, Vonjo, Cti Biopharma Corp
89808732030-03-25DS, DPU-3331, U-3332
81536322029-01-17DS, DPU-3331, U-3332
95739642028-05-05U-3331, U-3332
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EJ: Janus-associated kinase (jak) inhibitors
— L01EJ03: Pacritinib
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Primary myelofibrosisD055728D47.4553——11
Covid-19D000086382U07.1——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.023———4
Myelodysplastic syndromesD009190D4622———3
Myelomonocytic leukemia chronicD015477C93.122———3
LeukemiaD007938C95—2———2
Graft vs host diseaseD006086D89.8122———2
B-cell chronic lymphocytic leukemiaD015451C91.121———2
Lymphoproliferative disordersD008232Orphanet_2442D47.911———2
Mantle-cell lymphomaD020522C83.111———2
Hodgkin diseaseD006689C8111———2
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0—1———1
Show 7 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—5————5
Leukemia myeloid chronic atypical bcr-abl negativeD054438C92.21————1
Myelomonocytic leukemia juvenileD054429C93.31————1
Non-small-cell lung carcinomaD0022891————1
Waldenstrom macroglobulinemiaD008258C88.01————1
T-cell lymphoma peripheralD016411C84.91————1
T-cell lymphoma cutaneousD016410C84.A1————1
LymphomaD008223C85.91————1
B-cell lymphomaD0163931————1
Drug interactionsD0043471————1
Show 1 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePACRITINIB
INNpacritinib
Description
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Identifiers
PDB5LBZ
CAS-ID937272-79-2
RxCUI—
ChEMBL IDCHEMBL2035187
ChEBI ID—
PubChem CID46216796
DrugBankDB11697
UNII IDG22N65IL3O (ChemIDplus, GSRS)
Target
Agency Approved
JAK2
JAK2
Organism
Homo sapiens
Gene name
JAK2
Gene synonyms
NCBI Gene ID
3717
Protein name
tyrosine-protein kinase JAK2
Protein synonyms
JAK-2, Janus kinase 2, Janus kinase 2 (a protein tyrosine kinase)
Uniprot ID
O75297
Mouse ortholog
Jak2 (16452)
tyrosine-protein kinase JAK2 (Q7TQD0)
Alternate
JAK1
JAK1
FLT3
FLT3
JAK3
JAK3
NQO2
NQO2
Organism
Homo sapiens
Gene name
JAK1
Gene synonyms
JAK1A, JAK1B
NCBI Gene ID
3716
Protein name
tyrosine-protein kinase JAK1
Protein synonyms
JAK-1, Janus kinase 1
Uniprot ID
Q9UD26
Mouse ortholog
Jak1 (16451)
tyrosine-protein kinase JAK1 (P52332)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 714 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7 adverse events reported
View more details